2024
Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).
Mercier B, Tripathi N, Govindarajan A, Gebrael G, Narang A, Li X, Castro D, Chehrazi-Raffle A, Dizman N, Ebrahimi H, Chawla N, Hsu J, Bergerot C, Barragan-Carrillo R, Zengin Z, Meza L, Pal S, Agarwal N, Tripathi A. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2024, 42: 547-547. DOI: 10.1200/jco.2024.42.4_suppl.547.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaOverall survivalCox proportional hazards multivariate modelPresence of visceral metastasesChi-square test/Fisher's exact testIS groupPractice patternsPredictors of OSKaplan-Meier methodImpact practice patternsLog-rank testMedicare groupPrivate insuranceMulti-institutional studyANOVA/Kruskal-Wallis testVisceral metastasesInsurance payer statusNeoadjuvant chemotherapyNCI-designated comprehensive cancer centerSystemic therapyUrothelial carcinomaMedian ageBaseline characteristicsExact testClinical trial participation
2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Loo Gan C, Huang J, Pan E, Xie W, Schmidt A, Labaki C, Meza L, Bouchard G, Li H, Jackson-Spence F, Sánchez-Ruiz C, Powles T, Kumar S, Weise N, Hall W, Rose B, Beuselinck B, Suarez C, Pal S, Choueiri T, Heng D, McKay R. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2022, 6: 204-211. PMID: 36328934, DOI: 10.1016/j.euo.2022.10.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaMRCC treated with cabozantinibRenal cell carcinomaAdverse eventsRisk-benefit assessmentCell carcinomaReceiving radiotherapyInternational Metastatic Renal Cell Carcinoma Database ConsortiumPatients treated with stereotactic ablative body radiotherapyInternational multicenter retrospective studyStereotactic ablative body radiotherapyPractice patternsConventional palliative radiotherapyGrade 5 eventsIntermediate-risk diseaseReceipt of radiotherapyMultiple brain metastasesMetastatic kidney cancerRadiotherapy-related toxicityCourse of radiotherapyEfficacy of cabozantinibMulticenter retrospective studyStudy of patientsOptimize treatment outcomesAssessment of patients